Dr. Ian Thompson, MD, Honored on the San Antonio Movers and Shakers Show on News Talk 930 KLUP http://www.klup.com/
Bio from http://urology.uthscsa.edu/bio.html
"Dr. Ian Thompson, M.D.
ProfessorChairman, Department of UrologyGlenda and Gary Woods Distinguished Chair in GU OncologyHenry B. and Edna Smith Dielman Memorial Chair in Urologic ScienceEmail: thompsoni@uthscsa.eduAcademic Telephone: 210-567-5643Clinical Telephone: 210-450-1300Academic Fax: 210-567-6868Clinical Fax: 210-450-1749Faculty Profile
Biosketch
Dr. Ian Thompson received his undergraduate degree from West Point and his M.D. degree from Tulane University. After a Residency in Urology in San Antonio, he completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He is Chairman of the Department of Urology at the University of Texas Health Science Center at San Antonio. Dr. Thompson has published over 360 scientific papers, several dozen book chapters, and has edited five textbooks in medicine and surgery. He currently serves as Chair the Residency Review Committee for Urology and Vice-Chair of the Early Detection Research Network of the National Cancer Institute. He previously served as the President of the Society of Urologic Oncology, the international association of physicians who conduct research and who provide care for patients with urologic malignancies. He has served as a Visiting Professor at most major academic institutions in the U.S. as well as at many leading cancer centers in Europe, Asia, Central and South America, as well as Australia.
Dr. Thompson is the Principal Investigator of the San Antonio Center for Biomarkers Of Risk of Prostate Cancer. This cohort study, with up to 8 years of followup, currently follows over 3,600 men for development of prostate cancer and has been the source of many recent important developments in the early detection of prostate cancer. He was the primary coordinator of the 18,882-subject Prostate Cancer Prevention Trial, is the Localized Prostate Organ Site Chair for the Southwest Oncology Group, and has been PI or a co-investigator in several large national clinical trials. The Prostate Cancer Prevention Trial, sponsored by the National Cancer Institute, was the largest prostate cancer study ever conducted for prevention of prostate cancer and demonstrated that the medication, finasteride, was associated with a lower risk of prostate cancer.
Dr. Thompson retired as a Colonel from the U.S. Army, serving as Chairman of the Department of Surgery at Brooke Army Medical Center as well as Commander of the 41st Combat Support Hospital. He served in Saudi Arabia and Iraq as a General Surgeon in a Combat Support Hospital during Operation Desert Storm/Shield.
Patient Care
Dr. Thompson's primary expertise is the prevention, diagnosis, and treatment of Urologic malignancies including tumors of the kidney, bladder, prostate, testis and male genitalia. He is an internationally recognized expert in these tumors and patients and physicians seek his advice for the care of the most complex problems.
New Patients
To make an appointment, you may either visit the links at this website to make an appointment or simply call (210) 450-1300. We will make every effort to make a convenient appointment for you. Prior to your visit, we ask that you complete our initial visit form that details all aspects of your medical history as well as your current problems. Please fill out this form as completely as possible. When you come, we ask that you bring with you the additional items:
Any recent X-rays, CT scans, or other scans you have had. These should be the actual films themselves. Dr. Thompson prefers to examine the films himself in addition to examining the radiology reports.
Any records related to any pathology reports.
All pertinent laboratory test information.
A listing of all of your medications and dosages is also very important.
If you are not certain what to bring, either (1) call us at 210-450-1300 for advice or (2) bring all of your records with you. We want very much for your first visit to be as informative as possible and having all of this information at the time maximizes this likelihood.
For almost all visits, Dr. Thompson encourages family members, especially spouses or parents, to come the first time. It helps to have a 'second set of ears' as issues are discussed.
After hours contact information: You may find this at our web site but, when in doubt, simply call 210-450-1300. The answering service will put you in touch with either Dr. Thompson or one of his colleagues who, as necessary, will contact Dr. Thompson. To the extent possible, the faculty members of the Department of Urology want to know if their patients are having any problems and make themselves as accessible as possible. If you are having a medical emergency, it is best to call 911.
Healthcare Professionals
Dr. Thompson seeks to assist other physicians in the care of their patients. Consultations are made as rapidly as possible and both letters and full data of the visits are returned quickly to referring physicians. Should a fellow physician have a question concerning patient management, all physicians of the Department of Urology encourage telephone calls to discuss issues. The 210-450-1300 clinic number is an excellent 24-hour number. For academic issues, 210-567-5640 can be used during weekdays.
Our Promise and our Goal
All of the members of the Department of Urology feel that care of our patients is a privilege and a responsibility. We take this responsibility very seriously and have an overarching goal of providing the most state-of-the-art care for prevention, diagnosis, and treatment while providing this care in a very personal manner."
The following quote is from http://www.uthscsa.edu/hscnews/singleformat.asp?newID=2682
"SAN ANTONIO (Feb. 28, 2008) — The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is pleased to announce that Ian Thompson, M.D., director of the CTRC genitourinary clinic and professor and chairman of the Department of Urology at the UT Health Science Center School of Medicine, has been selected to serve as a co-chair for the National Cancer Institute (NCI) Genitourinary Steering Committee. Co-chair for NCI Genitourinary Steering CommitteeDr. Thompson was selected as one of three co-chairs for this distinguished leadership position because of his international reputation for prostate cancer research and due to the report of the Clinical Trials Working Group issued in 2004. In this report, the NCI provided recommendations on restructuring the clinical trials enterprise supported by the NCI. One of the initiatives set forth by the NCI was to establish a network of disease-specific scientific steering committees involving the broad oncology community.The three co-chairs of the Genitourinary Steering Committee include:
Dr. Thompson, representing urology
Dr. Anthony Zeitman (Massachusetts General Hospital), representing radiation oncology
And a medical oncologist yet to be named.The co-chairs of the steering committee are voting members and serve as leaders of the committee, guiding the committee’s direction. Among its many important tasks, the steering committee is responsible for reviewing protocol concepts and recommending approval, revision or disapproval of the concept to the Cancer Treatment Evaluation Program. The ultimate goal is for the NCI to move toward a comprehensive approach to the development, evaluation and prioritization of clinical trials in genitourinary cancers.
###The Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, located in San Antonio, Texas, is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute-Designated Cancer Center and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit http://www.ctrc.uthscsa.edu/.??
No comments:
Post a Comment